Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

IBA SA : IBA to Install Proton Therapy Center in V

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
(Total Views: 165)
Posted On: 07/05/2017 2:00:21 AM
Avatar
Posted By: News Desk 2018
IBA SA : IBA to Install Proton Therapy Center in Virginia, USA

IBA to Install Proton Therapy Center in Virginia, USA

Contract signed with Inova Health Care Services for two-room Proteus ® PLUS* proton therapy system near IBA's North American Headquarters

Reston, VA, USA, July 5 th , 2017 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, and Inova Health Care Services (Inova) today signed a contract for a two-room Proteus ® PLUS* proton therapy solution, each treatment room equipped with Pencil Beam Scanning capability and integrated Cone Beam CT.

The total value of the equipment and services supplied by IBA to Inova is approximately $60M. The project is fully financed and includes a long-term operation and maintenance contract. Inova plans to start treating patients by 2020.

Olivier Legrain, Chief Executive Officer of IBA SA, commented:  "We are pleased to announce that Inova has selected IBA as its proton therapy partner. IBA's proton therapy technology has been used to treat more cancer patients than any other proton therapy company in the world and we look forward to bringing this powerful cancer treatment tool to the patient community of Northern Virginia and beyond."

Beth Klein, President of IBA North America, added: "Inova's proton therapy project is unique in that it is located only 15 miles from IBA's North America Headquarters in Reston, Virginia, where we have the largest and most comprehensive Proton therapy support structure in the industry. Having the Inova center located near our North American office will facilitate collaboration with them as we work together to advance the use of proton therapy for those patients and families impacted by this devastating disease."

"The addition of proton therapy to our oncology services, will allow Inova to build upon our already strong local, national and international oncology services reach by providing one of the most significant technology innovations in the treatment of Cancer," added T homas Graves, Vice President for Cancer Services and Associate Director for Administration of the Inova Dwight and Martha Schar Cancer Institute . "The Center will be housed at Inova's Center for Personalized Health, offering patients easy access from anywhere in Virginia and the Metro DC area. This advanced technology will be an excellent complement to the best in class oncology services we will be offering at the facility."

Dr. Gopal Bajaj, Chairman and Medical Director of Radiation Oncology at Inova Dwight and Martha Schar Cancer Institute, added: "Being able to provide such a powerful cancer treatment truly puts Inova's radiation oncology department at the forefront of cancer treatment delivery. Proton therapy is an exciting alternative to traditional radiation treatment protocols, allowing us to treat many cancer patients more effectively, and often without the uncomfortable side effects that traditional treatments may cause. This technology will have a very positive impact on the thousands of people in our community who are touched by cancer."

***ENDS***

About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the Pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com  

*Proteus ® PLUS is the brand name of a configuration of the Proteus ® 235

About Inova Inova  is a global leader in personalized health, which leverages precision medicine to predict, prevent and treat disease, enabling individuals to live longer, healthier lives. Inova serves more than 2 million people each year throughout the Washington, DC, metro area and beyond. Inova's five hospitals include more than 1,700 licensed beds and 16,000 employees. Inova encompasses the full array of health services, including the area's only Level 1 Trauma Center and Level IV neonatal intensive care unit. Inova is also home to nationally and internationally recognized  Inova Heart and Vascular Institute (IHVI) ,  Inova Translational Medicine Institute (ITMI)  focused on genomics research,  Inova Neuroscience Institute , Inova Children's Hospital and Inova Schar Cancer Institute soon to include proton therapy.

For further information, please contact:

IBA Soumya Chandramouli Chief Financial Officer

Bernard Dandoy Investor Relations +32 10 475 890 Investorrelations@iba-group.com

Thomas Ralet Vice-President Corporate Communication +32 10 475 890 communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications Amber Fennell, Matthew Neal, Ivar Milligan +44 (0) 20 3709 5700 IBA@consilium-comms.com

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...6b640ba61f



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us